Since AKT regulates critical function in tumor cells, this protein is emerging as a clinically relevant target in cancer therapy.[73] Alongside the direct effect on tumor cells, blocking of AKT stimulates T cell functions, promoting the expansion of tumor‐specific lymphocytes.[74] Our data suggests that AKT blockers would also influence the TME by preventing the generation of M2‐like/pro‐tumoral macrophages, thereby favoring the anti‐tumor immune response while inhibiting the pro‐tumoral effects of these cells. Here, AKT1 is linked to neoplasm.